Active ingredientDuvelisibCat. No. P-D198-001CAS 1201438-56-3Family · Pharmaceutical analytical standards
Duvelisib
An oral inhibitor of the PI3K delta and gamma kinases, approved in the United States in 2018 and in the European Union in 2021 for relapsed or refractory forms of chronic lymphocytic leukaemia and lymphoma. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?It grew out of research in Kevan Shokat's laboratory at the University of California, San Francisco, on which the small company that discovered it was founded in 2007.
Go to the active ingredient →Active ingredientDuvelisibCat. No. P-D198-001CAS 1201438-56-3
MetaboliteDuvelisib N-GlucuronideCat. No. P-D198-002
Isotopically labelledDuvelisib-d5Cat. No. P-D198-003
NitrosamineN-Nitroso DuvelisibCat. No. P-D198-004
NitrosamineN-Nitroso ent-DuvelisibCat. No. P-D198-005
Impurityent-DuvelisibCat. No. P-D198-006CAS 1261590-48-0No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.